Vestibular Schwannoma: Results of Hypofractionated Stereotactic Radiation Therapy.
Journal
Advances in radiation oncology
ISSN: 2452-1094
Titre abrégé: Adv Radiat Oncol
Pays: United States
ID NLM: 101677247
Informations de publication
Date de publication:
Historique:
received:
03
11
2020
revised:
11
02
2021
accepted:
11
03
2021
entrez:
19
8
2021
pubmed:
20
8
2021
medline:
20
8
2021
Statut:
epublish
Résumé
Our purpose was to study the outcomes of hypofractionated stereotactic radiation therapy (HSRT) in terms of hearing and radiologic response for vestibular schwannomas. This was a longitudinal retrospective study at a referral center from 2011 to 2016. All treatments were performed on a Cyberknife device with a dose of 21 Gy (3 × 7 Gy) or 25 Gy (5 × 5 Gy). We assessed tumor response, neurologic outcomes (hearing and facial nerve function), and treatment toxicity. A total of 82 patients were included. Fifty-three patients were treated with the 3 × 7 Gy scheme and 29 with the 5 × 5 Gy. Sixteen patients (20%) had a previous surgery. The median follow-up was 48 months (range, 12-88 months). We noted 3 recurrences leading to a control rate of 96.3%. In our cohort, predictive factors of vestibular schwannoma growth were a tumor volume >2 mm Our results suggest that HSRT using 3 or 5 fractions is a well-tolerated and effective regimen. These findings are in addition to the few previous hypofractionation studies and contribute to the validity of this treatment modality.
Identifiants
pubmed: 34409203
doi: 10.1016/j.adro.2021.100694
pii: S2452-1094(21)00052-X
pmc: PMC8361054
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100694Informations de copyright
© 2021 The Author(s).
Références
Neurosurgery. 2013 Sep;73(3):489-96
pubmed: 23756743
J Neurosurg. 2011 Dec;115(6):1078-86
pubmed: 21961962
Singapore Med J. 2018 Nov;59(11):590-596
pubmed: 30182129
Rep Pract Oncol Radiother. 2016 Jul-Aug;21(4):399-406
pubmed: 27330427
Strahlenther Onkol. 2017 Mar;193(3):192-199
pubmed: 27803960
J Neurosurg. 2013 Mar;118(3):557-65
pubmed: 23140152
J Neurosurg. 2010 Dec;113 Suppl:105-11
pubmed: 21121792
Int J Radiat Oncol Biol Phys. 2011 Aug 1;80(5):1485-91
pubmed: 20708852
Int J Radiat Oncol Biol Phys. 2003 Aug 1;56(5):1390-6
pubmed: 12873685
Neurosurgery. 2001 Dec;49(6):1299-306; discussion 1306-7
pubmed: 11846928
Front Oncol. 2013 May 17;3:121
pubmed: 23730624
Lancet Oncol. 2019 Jan;20(1):159-164
pubmed: 30473468
J Neurooncol. 2014 Jan;116(1):187-93
pubmed: 24142200
Eur Arch Otorhinolaryngol. 2015 Nov;272(11):3187-92
pubmed: 25359198
Front Oncol. 2017 Sep 04;7:200
pubmed: 28929084
Otol Neurotol. 2008 Jan;29(1):46-9
pubmed: 18046259
Stereotact Funct Neurosurg. 1999;73(1-4):45-9
pubmed: 10853097
N Engl J Med. 1998 Nov 12;339(20):1426-33
pubmed: 9811917
Neurosurgery. 2003 Aug;53(2):282-87; discussion 287-8
pubmed: 12925242
Radiother Oncol. 2013 Feb;106(2):169-74
pubmed: 23219253
Int J Radiat Oncol Biol Phys. 2010 Jan 1;76(1):193-200
pubmed: 19604653
Neurosurgery. 2011 Dec;69(6):1200-9
pubmed: 21558974
J Neurosurg. 2011 Feb;114(2):381-5
pubmed: 20486891
Neurosurgery. 2005 Jun;56(6):1254-61; discussion 1261-3
pubmed: 15918941
World Neurosurg. 2013 Sep-Oct;80(3-4):359-63
pubmed: 22484770
Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):e503-9
pubmed: 21665381
Int J Radiat Oncol Biol Phys. 2011 Nov 1;81(3):647-53
pubmed: 20884130
Radiother Oncol. 2015 Mar;114(3):378-83
pubmed: 25702864
Clin Neurol Neurosurg. 2018 Mar;166:116-123
pubmed: 29414150
Otol Neurotol. 2014 Jan;35(1):162-70
pubmed: 24335934
Biomed Res Int. 2013;2013:297093
pubmed: 24312910
Acta Neurochir (Wien). 2002 Dec;144(12):1249-54; discussion 1254
pubmed: 12478335
Neurosurgery. 2013 Jul;73(1):48-56; discussion 56-7
pubmed: 23615094
Otolaryngol Clin North Am. 2012 Apr;45(2):257-68, vii
pubmed: 22483814
Int J Radiat Oncol Biol Phys. 2001 Aug 1;50(5):1265-78
pubmed: 11483338
Int J Radiat Oncol Biol Phys. 2016 Jun 1;95(2):721-8
pubmed: 26960748
Int J Radiat Oncol Biol Phys. 2021 May 1;110(1):100-111
pubmed: 33375955